The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease
Status:
Completed
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
The study is to further exploring the optimal switching strategy by evaluating the
pharmacodynamic responses as well as adverse events in patients with complexity of coronary
artery disease managed by percutaneous coronary intervention (PCI). All participants will be
divided into three groups and recieving ticagrelor 90mg plus aspirin 100mg at 12 hours after
the last dose of clopidogrel; recieving ticagrelor 90mg plus aspirin 100mg at 24 hours after
the last dose of clopidogrel; recieving ticagrelor 180mg plus aspirin 100mg at 24 hours after
the last dose of clopidogrel.